Monday January 12, 2015 0 comments
LOUISVILLE - AntriaBio Inc. (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, announced Dr. Hoyoung Huh, one of the company's co-founders and member of its board of directors, has been named chair of AntriaBio's business development, product pipeline strategy and Scientific Advisory Board.
"AntriaBio has tremendous potential to transform the therapeutic regimen in diabetes and significantly improve the standard of care in other disease states," Huh said.
"The company has matured and achieved critical milestones over the past 12 months, including compelling preclinical studies in multiple animal species for is lead product candidate, AB101."
In his expanded role, Huh will partner with longtime colleague Nevan Elam, company chairman and CEO, and Dr. Sankaram Mantripragada, CSO.
"We are very excited to have Hoyoung join us in a more direct capacity as we seek to broaden AntriaBio's vision and strategy," said Elam. "Hoyoung is a widely respected visionary and entrepreneur in our industry. His insights and direction will be invaluable as we head into the next phase of our growth."